Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
50.45
+5.18 (+11.44%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
February 29, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
February 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
February 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
February 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
February 05, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
February 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 30, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
January 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...
Via
TheNewswire.com
Exposures
Product Safety
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
January 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
January 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
January 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
January 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.